WallStSmart

LifeMD Inc (LFMD)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 1174% more annual revenue ($2.46B vs $193.33M). LFMD leads profitability with a 2.9% profit margin vs -2.5%. RCM earns a higher WallStSmart Score of 39/100 (F).

LFMD

Avoid

23

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -1.68

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LFMD.

RCMUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$19.79

Current Price

$14.31

$5.48 discount

UndervaluedFair: $19.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LFMD0 strengths · Avg: 0/10

No standout strengths identified

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

LFMD4 concerns · Avg: 3.5/10
Price/BookValuation
14.2x4/10

Trading at 14.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$236.49M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : LFMD

LFMD has a balanced fundamental profile.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : LFMD

The primary concerns for LFMD are Price/Book, EPS Growth, Market Cap. Thin 2.9% margins leave little buffer for downturns.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

LFMD profiles as a value stock while RCM is a turnaround play — different risk/reward profiles.

LFMD carries more volatility with a beta of 1.99 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

RCM scores higher overall (39/100 vs 23/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

LifeMD Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

LifeMD, Inc. is a direct-to-patient telehealth company connecting consumers with healthcare professionals for care in various indications, including concierge care, men's sexual health, dermatology, and others in the United States. . The company is headquartered in New York, New York.

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-driven revenue cycle management solutions that significantly enhance the financial performance of healthcare organizations across the United States. By leveraging advanced analytics and deep industry expertise, R1 RCM offers comprehensive services that optimize billing processes and improve operational efficiency for hospitals and outpatient facilities alike. The company’s innovative approach not only enhances revenue capture but also elevates patient experiences, establishing R1 RCM as a critical player in the evolving healthcare sector. With a strong emphasis on expanding its service offerings and increasing market share, R1 RCM is strategically positioned to capitalize on the growing demand for sophisticated revenue cycle management services.

Want to dig deeper into these stocks?